Literature DB >> 2552143

The regions important for the activator and repressor functions of herpes simplex virus type 1 alpha protein ICP27 map to the C-terminal half of the molecule.

M A Hardwicke1, P J Vaughan, R E Sekulovich, R O'Conner, R M Sandri-Goldin.   

Abstract

The herpes simplex virus type 1 (HSV-1) alpha or immediate-early proteins ICP4 (IE175), ICP0 (IE110), and ICP27 (IE63) are trans-acting proteins which affect HSV-1 gene expression. We previously showed that ICP27 in combination with ICP4 and ICP0 could act as a repressor or an activator in transfection assays, depending on the target gene (R. E. Sekulovich, K. Leary, and R. M. Sandri-Goldin, J. Virol. 62:4510-4522, 1988). To investigate the regions of the ICP27 protein which specify these functions, we constructed a series of in-frame insertion and deletion mutants in the ICP27 gene. These mutants were analyzed in transient expression assays for the ability to repress or to activate two different target genes. The target plasmids used consisted of the promoter regions from the HSV-1 beta or early gene which encodes thymidine kinase and from the beta-gamma or leaky late gene. VP5, which encodes the major capsid protein, each fused to the chloramphenicol acetyltransferase gene. Our previous studies showed that induction of pTK-CAT expression by ICP4 and ICP0 was repressed by ICP27, whereas the stimulation of pVP5-CAT expression seen with ICP4 and ICP0 was significantly increased when ICP27 was also added. In this study, a series of transfection assays was performed with each of the ICP27 mutant plasmids in combination with plasmids containing the ICP4 and ICP0 genes with each target. The results of these experiments showed that mutants containing insertions or deletions in the region from amino acids 262 to 406 in the carboxy-terminal half of the protein were unable to stimulate expression of pVP5-CAT but were able to repress induction of pTK-CAT activity by ICP4 and ICP0. Mutants in the carboxy-terminal 78 amino acids lost both activities; that is, these mutants did not show repression of pTK-CAT activity or stimulation of pVP5-CAT activity, whereas mutants in the hydrophilic amino-terminal half of ICP27 were able to perform both functions. These results show that the carboxy-terminal half of ICP27 is important for the activation and repression functions. Furthermore, the carboxy-terminal 62 amino acids are required for the repressor activity, because mutants with this region intact were able to repress. Analysis of the DNA sequence showed that there are a number of cysteine and histidine residues encoded by this region which have some similarity to zinc finger metal-binding regions found in other eucaryotic regulatory proteins. These results suggest that the structural integrity of this region is important for the function of ICP27.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2552143      PMCID: PMC251092          DOI: 10.1128/JVI.63.11.4590-4602.1989

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  88 in total

1.  Direct correlation between a negative autoregulatory response element at the cap site of the herpes simplex virus type 1 IE175 (alpha 4) promoter and a specific binding site for the IE175 (ICP4) protein.

Authors:  M S Roberts; A Boundy; P O'Hare; M C Pizzorno; D M Ciufo; G S Hayward
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

2.  The function and structure of the metal coordination sites within the glucocorticoid receptor DNA binding domain.

Authors:  L P Freedman; B F Luisi; Z R Korszun; R Basavappa; P B Sigler; K R Yamamoto
Journal:  Nature       Date:  1988-08-11       Impact factor: 49.962

3.  Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient.

Authors:  A M McCarthy; L McMahan; P A Schaffer
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

4.  Analysis of the functional domains of herpes simplex virus type 1 immediate-early polypeptide Vmw110.

Authors:  R D Everett
Journal:  J Mol Biol       Date:  1988-07-05       Impact factor: 5.469

5.  The herpes simplex virus type 1 alpha protein ICP27 can act as a trans-repressor or a trans-activator in combination with ICP4 and ICP0.

Authors:  R E Sekulovich; K Leary; R M Sandri-Goldin
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

6.  Role for DNA-protein interaction in activation of the herpes simplex virus glycoprotein D gene.

Authors:  D G Tedder; L I Pizer
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

7.  Gene-specific transactivation by herpes simplex virus type 1 alpha protein ICP27.

Authors:  S A Rice; D M Knipe
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

8.  Mutational dissection of the HSV-1 immediate-early protein Vmw175 involved in transcriptional transactivation and repression.

Authors:  T Paterson; R D Everett
Journal:  Virology       Date:  1988-09       Impact factor: 3.616

9.  Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif.

Authors:  A J Courey; R Tjian
Journal:  Cell       Date:  1988-12-02       Impact factor: 41.582

10.  The N-terminal DNA-binding 'zinc finger' of the oestrogen and glucocorticoid receptors determines target gene specificity.

Authors:  S Green; V Kumar; I Theulaz; W Wahli; P Chambon
Journal:  EMBO J       Date:  1988-10       Impact factor: 11.598

View more
  56 in total

1.  Herpesvirus mRNAs are sorted for export via Crm1-dependent and -independent pathways.

Authors:  T M Soliman; S J Silverstein
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Processing of alpha-globin and ICP0 mRNA in cells infected with herpes simplex virus type 1 ICP27 mutants.

Authors:  K S Ellison; S A Rice; R Verity; J R Smiley
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Functional analysis of Epstein-Barr virus SM protein: identification of amino acids essential for structure, transactivation, splicing inhibition, and virion production.

Authors:  Vivian Ruvolo; Liang Sun; Karilynn Howard; Seung Sung; Henri-Jacques Delecluse; Wolfgang Hammerschmidt; Sankar Swaminathan
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

4.  Herpes simplex virus IE63 acts at the posttranscriptional level to stimulate viral mRNA 3' processing.

Authors:  J McLauchlan; A Phelan; C Loney; R M Sandri-Goldin; J B Clements
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

5.  Immediate-early expression of the herpes simplex virus type 1 ICP27 transcript is not critical for efficient replication in vitro or in vivo.

Authors:  Aixu Sun; G V Devi-Rao; M K Rice; L W Gary; D C Bloom; R M Sandri-Goldin; P Ghazal; E K Wagner
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

6.  UL54-null pseudorabies virus is attenuated in mice but productively infects cells in culture.

Authors:  Jennifer A Schwartz; Elizabeth E Brittle; Ashley E Reynolds; Lynn W Enquist; Saul J Silverstein
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

7.  Herpes simplex virus trans-regulatory protein ICP27 stabilizes and binds to 3' ends of labile mRNA.

Authors:  C R Brown; M S Nakamura; J D Mosca; G S Hayward; S E Straus; L P Perera
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  The herpes simplex virus regulatory protein ICP27 contributes to the decrease in cellular mRNA levels during infection.

Authors:  M A Hardwicke; R M Sandri-Goldin
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  UL69 of human cytomegalovirus, an open reading frame with homology to ICP27 of herpes simplex virus, encodes a transactivator of gene expression.

Authors:  M Winkler; S A Rice; T Stamminger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

10.  The conserved DNA-binding domains encoded by the herpes simplex virus type 1 ICP4, pseudorabies virus IE180, and varicella-zoster virus ORF62 genes recognize similar sites in the corresponding promoters.

Authors:  C L Wu; K W Wilcox
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.